NCT04915768View on ClinicalTrials.gov

Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants.

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

January 23, 2023

Primary Completion Date

July 15, 2025

Study Completion Date

July 15, 2025

Conditions
HIV Infections
Interventions
BIOLOGICAL

CH505 TF chTrimer

Combined with adjuvants 3M-052-AF and Alum. Combination administered as two 0.5 mL doses via intramuscular injection into deltoid muscle.

BIOLOGICAL

3M-05-AF

Combined with CH505 TF chTrimer and Alum adjuvant. Combination administered as two 0.5 mL doses via intramuscular injection into deltoid muscle.

BIOLOGICAL

Aluminum hydroxide suspension

Combined with CH505 TF chTrimer and 3M-052-AF adjuvant. Combination administered as two 0.5 mL doses via intramuscular injection into deltoid muscle

Trial Locations (3)

30030

The Hope Clinic of the Emory Vaccine Center CRS, Decatur

Vanderbilt Vaccine (VV) CRS, Nashville

02115

Brigham and Women's CRS, Boston

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH